Repinotan

Last updated
Repinotan
Repinotan.svg
Clinical data
Routes of
administration 		Oral
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • (R)-(−)-2-[4-[(chroman-2-ylmethyl)-amino]-butyl]-1,1-dioxo-benzo[d]isothiazolone
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C21H24N2O4S
Molar mass 400.49 g·mol−1
3D model (JSmol)
  • C1CC2=CC=CC=C2O[C@H]1CNCCCCN3C(=O)C4=CC=CC=C4S3(=O)=O
  • InChI=1S/C21H24N2O4S/c24-21-18-8-2-4-10-20(18)28(25,26)23(21)14-6-5-13-22-15-17-12-11-16-7-1-3-9-19(16)27-17/h1-4,7-10,17,22H,5-6,11-15H2/t17-/m1/s1 X mark.svgN
  • Key:YGYBFMRFXNDIPO-QGZVFWFLSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Repinotan (BAYx3702), an aminomethylchroman derivative, is a selective 5-HT1A receptor full agonist with high potency and efficacy. [1] [2] It has neuroprotective effects in animal studies, [3] [4] [5] and was trialed in humans for reducing brain injury following head trauma. [6] It was subsequently trialed up to phase II for treatment of stroke, but while side effects were mild and consisted mainly of nausea, repinotan failed to demonstrate sufficient efficacy to justify further clinical trials. [7] [8] [9] However, repinotan continues to be investigated for other applications, and was found to be effective at counteracting the respiratory depression produced by morphine, though with slight reduction in analgesic effects. [10]

Contents

Medical uses

Acute ischemic stroke

Repinotan was originally developed by Bayer Healthcare AG (Wuppertal, Germany) as an oral treatment for depression. [11] However, it was instead trialed as a candidate for reducing brain injury following head trauma. The drug was then examined as a preventative of secondary brain damage for ischemic stroke victims. Early trials showed repinotan's ability to reduce hippocampal CA1 and CA3 neuronal loss. Cortical tissue damage was also reduced. In addition, repinotan was shown to mitigate spatial learning deficits. [12] However, trials were discontinued due to repinotan's efficacy being insufficient. [13]

Respiratory depression

Repinotan Dose Relationship to Nociception Repinotan Dose Relationship to Nociception.png
Repinotan Dose Relationship to Nociception

Repinotan has presently been found to be effective at stopping respiratory depression caused by morphine. In addition, it represses nociception at high doses, but enhances nociception at small doses (0.2 micrograms/kg). [10] Repinotan may be applicable to Parkinson's, as it is able to reduce glutamate-induced excitotoxicity and thereby some cell death. [14]

Additional uses

Another stroke medication trialed at the same time, picozotan, is similar to repinotan in that it is also a serotonin agonist. Other drugs included zonampanel, which acts as an AMPA receptor antagonist instead of a 5-HT1A receptor agonist and DP-b99. DP-b99 is a metal iron chelator. [15]

Side effects

Repinotan's side effects during trials as a treatment for ischemic stroke consisted mainly of serotonergic side effects including nausea and vomiting. The most common side effect was headache. Neurological worsening, cerebral hemorrhage, and brain edema were the most common severe effects. However, repinotan was generally shown to be safe. [16]

Its current investigation as an antagonist for respiratory depression caused by morphine has shown there to be no serious cardiovascular side effects. However, a slight decrease in blood pressure was a more minor effect. [10] Repinotan has been linked with pupil diameter reduction. [17]

Pharmacology

Mechanism of action

Repinotan HCI (BAYx3702) acts as a highly selective 5-HT1A receptor full agonist. It is blocked by the specific 5-HT1A receptor antagonist, WAY 100135 [10] and its primary metabolizer is CYP2D6. Ethnic differences are known to have an effect on CYP2D6. Repinotan is believed to operate through neuronal hyperpolarization. [18]

When repinotan first binds to both pre- and post-synaptic 5-HT1A receptors, G protein-coupled inwardly rectifying K+ channels are activated. This causes hyperpolarization. Because hyperpolarization causes inhibition of neuron firing and less glutamate release, neurons are protected against overexcitation. This could explain repinotan's neuroprotective properties. [8]

In addition, the protein Bcl-2, the serotonergic glial growth factor S-100beta, and Nerve Growth Factor are affected by repinotan. [8] Repinotan is able to suppress caspase-3 through MAPK and PKCalpha. [19] Apoptosis as a result of anoxia/reoxygenation and H(2)O(2) treatment may also be inhibited. [20]

Repinotan has been found to bind with high to moderate affinity to the receptors alpha-1 and alpha-2 adrenergic, 5-HT7- and 5-HT1D, dopamine D2 and D4, sigma sites, and 5-HT2C. It is able to increase activity of VTA dopaminergic neurons and medial prefrontal cortex dopamine release. [21]

Pharmacodynamics

Repinotan acts as a selective high-affinity full receptor agonist at the 5-HT1A receptor subtype. [13] It increases the activity of dopamine (DA) neurons in the ventral tegmental area as well as DA release in the medial prefrontal cortex. [22]

Additionally, it is an extremely potent drug and is able to cross the blood-brain barrier. After infusion, the distribution equilibrium between plasma and brain is reached almost instantaneously. [23]

Repinotan's efficacy is mainly dependent on factors such as the length of time between the start of stroke symptoms and taking the drug. The age and blood pressure of the patient also plays a role. Decreases in response with increasing age as well as decreases in response as blood pressure increases are generally observed. [24] The most efficient dose is approximately 1.25 mg per day. [16]

Pharmacokinetics

Repinotan's primary route of administration is by intravenous injection, [13] which indicates that it goes directly into the bloodstream. It is able to cross the blood-brain barrier- a highly selective barrier that separates circulating blood from the brain's extracellular fluid. Diffusion acts as the driving force, which allows repinotan to cross in both directions. In addition, the drug is uncharged, which is consistent with the fact that it is able to pass the lipophilic and non-polar blood-brain barrier. [23]

The half-life of repinotan is approximately 1 hour. Elimination ensues in parallel from plasma and brain. In addition, repinotan's volume of distribution at steady-state and plasma clearance are independent of dose. This is indicative of linear pharmacokinetics over the range of 0.1-3.0 micrograms repinotan/kg/h. [25]

Infusion rates of up to 150 microg/h are well received. [26] Repinotan's optimal dose is 1.25 mg/day. [16]

Gender and age do not have any influence on repinotan's pharmacokinetics. Bodyweight also does not play a big role. [26]

Chemistry

Properties

Repinotan is an enantiomerically pure aminomethyl chromane derivative with a saccharinylbutyl substituent. [27] It is classified as a synthetic organic and possesses five hydrogen bond acceptors and one hydrogen bond donor. Its topological polar surface area is 84.09 and it has seven rotatable bonds. In addition, its molecular weight is 400.15 g/mole. Repinotan has a formal charge of zero and a covalently-bonded unit count of one. It is similar in chemical and physical properties to the ligands quetiapine, PAT5A, and pioglitazone. [28]

Synthesis

Bayer Healthcare AG synthesized Repinotan in three main reaction sequences. A form with a metabolically stable 14carbon-label was necessary for pharmacokinetic studies. The hydrochloride was hydroxylated in the 6-position of the chromane moiety. [27]

For the first reaction sequence, [14C]-phenol was used as the starting compound. Michael adduct formation was then employed in the preparation of chromane rings with [14C]-phenol. [27]

In the second reaction sequence, [Carbonyl-14C]-2-hydroxy-acetophenone was used first. Compound XII was formed from condensation of [carbonyl-14C-]-2-hydroxy-acetophenone with dimethyl oxylate and ring closure. Hydrogenolytical debenzylation and hydrochloric acid created the final product. [27]

The third reaction involved intermediate XVII undergoing acylation using acetyl chloride. Deacetylation and debenzylation were then implemented with HCI. Pd/C was used in the deacetylation step and Pd/C was used in the debenzylation step. [27]

Patent (Ex 92): Crystalline form: Radiolabelled: Revised: Repinotan synthesis.svg
Patent (Ex 92): Crystalline form: Radiolabelled: Revised:

The last step in the synthesis involves the reaction between (R)-2-aminomethylchroman [404337-71-9] (1) and N-(4-bromobutyl)saccharin [103564-59-6] (2).

History

Bayer Healthcare AG (Wuppertal, Germany) first synthesized repinotan during early 2000s. As of 2004, it was expected to be filed by the NDA. Phase III trials for both ischemic stroke and traumatic brain injury were run in March 2002. [11] However, these trials found the drug ineffective as a treatment (November, 2009). [13]

In October 2010, further investigation showed repinotan able to counteract respiratory depression caused by morphine. Repinotan continues to be examined, but has not yet been commercially released. [10]

Currently, repinotan is not commercially available in the United States. Sales of $1000 million in the U.S. and a launch date of 2006 were originally anticipated by Lehman Brothers. Bank Vontobel and Bayer both estimated sales of 450 million Euros. However, the drug continues to be under investigation for different treatments than its original intent. [11]

See also

Related Research Articles

<span class="mw-page-title-main">Aripiprazole</span> Atypical antipsychotic

Aripiprazole, sold under the brand names Abilify and Aristada, among others, is an atypical antipsychotic. It is primarily used in the treatment of schizophrenia, obsessive compulsive disorder (OCD), and bipolar disorder; other uses include as an add-on treatment in major depressive disorder, tic disorders, and irritability associated with autism. Aripiprazole is taken by mouth or via injection into a muscle. A Cochrane review found low-quality evidence of effectiveness in treating schizophrenia.

<span class="mw-page-title-main">Azapirone</span> Drug class of psycotropic drugs

Azapirones are a class of drugs used as anxiolytics, antidepressants, and antipsychotics. They are commonly used as add-ons to other antidepressants, such as selective serotonin reuptake inhibitors (SSRIs).

<span class="mw-page-title-main">Bifeprunox</span> Experimental dopamine D2 receptor partial agonist researched as an antipsychotic agent

Bifeprunox (INN) (code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D2 receptor agonism with serotonin receptor agonism. It was under development for the treatment of schizophrenia but has since been abandoned.

5-HT<sub>1A</sub> receptor Serotonin receptor protein distributed in the cerebrum and raphe nucleus

The serotonin 1A receptor is a subtype of serotonin receptors, or 5-HT receptors, that binds serotonin, also known as 5-HT, a neurotransmitter. 5-HT1A is expressed in the brain, spleen, and neonatal kidney. It is a G protein-coupled receptor (GPCR), coupled to the Gi protein, and its activation in the brain mediates hyperpolarization and reduction of firing rate of the postsynaptic neuron. In humans, the serotonin 1A receptor is encoded by the HTR1A gene.

<span class="mw-page-title-main">WAY-100635</span> Chemical compound

WAY-100635 is a piperazine drug and research chemical widely used in scientific studies. It was originally believed to act as a selective 5-HT1A receptor antagonist, but subsequent research showed that it also acts as potent full agonist at the D4 receptor. It is sometimes referred to as a silent antagonist at the former receptor. It is closely related to WAY-100135.

<span class="mw-page-title-main">BAY 38-7271</span> Chemical compound

Originally synthesized by chemist Wayne E. Kenney, BAY 38-7271 (KN 38-7271) is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury. It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB1 and CB2 receptors, with Ki values of 2.91nM at CB1 and 4.24nM at CB2. It has been licensed to KeyNeurotek Pharmaceuticals for clinical development, and was in Phase II trials in 2008 but its development appears to have stopped.

<span class="mw-page-title-main">Ispronicline</span> Chemical compound

Ispronicline is an experimental drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It progressed to phase II clinical trials for the treatment of dementia and Alzheimer's disease, but is no longer under development.

<span class="mw-page-title-main">GTS-21</span> Chemical compound

GTS-21 is an investigational drug that has been studied for its potential therapeutic uses, particularly in the treatment of neurodegenerative diseases and psychiatric disorders.

<span class="mw-page-title-main">Lubeluzole</span> Chemical compound

Lubeluzole (Prosynap) is a drug which acts as an indirect NMDA antagonist. It inhibits the release of glutamate, inhibits nitric oxide synthesis, and blocks calcium and sodium gated ion channels. It has neuroprotective effects particularly in hypoxic conditions, and was developed for the treatment of stroke. Trials showed it to be safe, effective and well tolerated at low doses, but unfortunately higher doses produced the dangerous cardiac side effect of lengthening the QTc interval, which could potentially lead to heart failure, and so this meant that subsequent trials were limited to using only the low dose range. Animal studies had shown lubeluzole to produce neuroprotective effects when administered for prolonged periods, but the aim of its developers was to produce a drug that would be effective for preventing damage from acute stroke, and so ultimately it failed to show sufficient efficacy in trials and development for medical use was halted.

<span class="mw-page-title-main">Befiradol</span> Chemical compound

Befiradol is an experimental drug being studied for the treatment of levodopa-induced dyskinesia. It is a potent and selective 5-HT1A receptor full agonist.

<span class="mw-page-title-main">Dexanabinol</span> Chemical compound

Dexanabinol is a synthetic cannabinoid derivative in development by e-Therapeutics plc. It is the "unnatural" enantiomer of the potent cannabinoid agonist HU-210. Unlike other cannabinoid derivatives, HU-211 does not act as a cannabinoid receptor agonist, but instead as an NMDA antagonist. It therefore does not produce cannabis-like effects, but is anticonvulsant and neuroprotective, and is widely used in scientific research as well as currently being studied for applications such as treating head injury, stroke, or cancer. It was shown to be safe in clinical trials and is currently undergoing Phase I trials for the treatment of brain cancer and advanced solid tumors.

<span class="mw-page-title-main">Eptapirone</span> Chemical compound

Eptapirone (F-11,440) is a very potent and highly selective 5-HT1A receptor full agonist of the azapirone family. Its affinity for the 5-HT1A receptor was reported to be 4.8 nM (Ki), and its intrinsic activity approximately equal to that of serotonin.

<span class="mw-page-title-main">Piclozotan</span> Chemical compound

Piclozotan (SUN-N4057) is a selective 5-HT1A receptor partial agonist, which has neuroprotective effects in animal studies. It has been through early clinical trials in humans for treatment of acute stroke, but results have not yet been announced.

<span class="mw-page-title-main">Osemozotan</span> Pharmaceutical drug

Osemozotan (MKC-242) is a selective 5-HT1A receptor agonist with some functional selectivity, acting as a full agonist at presynaptic and a partial agonist at postsynaptic 5-HT1A receptors. 5-HT1A receptor stimulation influences the release of various neurotransmitters including serotonin, dopamine, norepinephrine, and acetylcholine. 5-HT1A receptors are inhibitory G protein-coupled receptor. Osemozotan has antidepressant, anxiolytic, antiobsessional, serenic, and analgesic effects in animal studies, and is used to investigate the role of 5-HT1A receptors in modulating the release of dopamine and serotonin in the brain, and their involvement in addiction to abused stimulants such as cocaine and methamphetamine.

<span class="mw-page-title-main">Cariprazine</span> Atypical antipsychotic medicine

Cariprazine, sold under the brand names Vraylar and Reagila among others, is an atypical antipsychotic originated by Gedeon Richter, which is used in the treatment of schizophrenia, bipolar mania, bipolar depression, and major depressive disorder. It acts primarily as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. Cariprazine is also a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors, with high selectivity for the D3 receptor. It is taken by mouth.

<span class="mw-page-title-main">Gavestinel</span> Chemical compound

Gavestinel (GV-150,526) was an investigational drug developed by GlaxoSmithKline for acute intracerebral hemorrhage, which in 2001 failed to show an effect in what was at the time, the largest clinical trial in stroke that had been conducted.

<span class="mw-page-title-main">Brexpiprazole</span> Atypical antipsychotic

Brexpiprazole, sold under the brand name Rexulti among others, is a medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease. It is an atypical antipsychotic.

<span class="mw-page-title-main">Lomerizine</span> Chemical compound

Lomerizine (INN) is a diphenylpiperazine class L-type and T-type calcium channel blocker. This drug is currently used clinically for the treatment of migraines, while also being used experimentally for the treatment of glaucoma and optic nerve injury.

<span class="mw-page-title-main">Aripiprazole lauroxil</span> Chemical compound

Aripiprazole lauroxil, sold under the brand name Aristada, is a long-acting injectable atypical antipsychotic that was developed by Alkermes. It is an N-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to eight weeks for the treatment of schizophrenia. Aripiprazole lauroxil was approved by the U.S. Food and Drug Administration (FDA) on 5 October 2015.

A cerebroprotectant is a drug that is intended to protect the brain after the onset of acute ischemic stroke. As stroke is the second largest cause of death worldwide and a leading cause of adult disability, over 150 drugs tested in clinical trials to provide cerebroprotection.

References

  1. ↑ De Vry J, Schohe-Loop R, Heine HG, Greuel JM, Mauler F, Schmidt B, et al. (March 1998). "Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist". The Journal of Pharmacology and Experimental Therapeutics. 284 (3): 1082–1094. PMID   9495870.
  2. ↑ Dong J, de Montigny C, Blier P (September 1998). "Full agonistic properties of BAY x 3702 on presynaptic and postsynaptic 5-HT1A receptors electrophysiological studies in the rat hippocampus and dorsal raphe". The Journal of Pharmacology and Experimental Therapeutics. 286 (3): 1239–1247. PMID   9732384.
  3. ↑ Alessandri B, Tsuchida E, Bullock RM (October 1999). "The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat". Brain Research. 845 (2): 232–235. doi:10.1016/S0006-8993(99)01948-4. PMID   10536203. S2CID   36341439.
  4. ↑ Kline AE, Yu J, Horváth E, Marion DW, Dixon CE (2001). "The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats". Neuroscience. 106 (3): 547–555. doi:10.1016/S0306-4522(01)00300-1. PMID   11591455. S2CID   54308982.
  5. ↑ Mauler F, Horváth E (April 2005). "Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury". Journal of Cerebral Blood Flow and Metabolism. 25 (4): 451–459. doi: 10.1038/sj.jcbfm.9600038 . PMID   15674237.
  6. ↑ Ohman J, Braakman R, Legout V, et al. (Traumatic Brain Injury Study Group) (December 2001). "Repinotan (BAY x 3702): a 5HT1A agonist in traumatically brain injured patients". Journal of Neurotrauma. 18 (12): 1313–1321. doi:10.1089/08977150152725614. PMID   11780862.
  7. ↑ Lutsep HL (April 2005). "Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke". Current Drug Targets. CNS and Neurological Disorders. 4 (2): 119–120. doi:10.2174/1568007053544165. PMID   15857296.
  8. 1 2 3 Berends AC, Luiten PG, Nyakas C (2005). "A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAYx3702) in ischemic stroke". CNS Drug Reviews. 11 (4): 379–402. doi:10.1111/j.1527-3458.2005.tb00055.x. PMC   6741728 . PMID   16614737.
  9. ↑ Teal P, Davis S, Hacke W, Kaste M, Lyden PD, Fierus M, et al. (Modified Randomized Exposure Controlled Trial Study Investigators) (November 2009). "A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT)". Stroke. 40 (11): 3518–3525. doi: 10.1161/STROKEAHA.109.551382 . PMID   19745176.
  10. 1 2 3 4 5 Guenther U, Wrigge H, Theuerkauf N, Boettcher MF, Wensing G, Zinserling J, et al. (October 2010). "Repinotan, a selective 5-HT1A-R-agonist, antagonizes morphine-induced ventilatory depression in anesthetized rats". Anesthesia and Analgesia. 111 (4): 901–907. doi: 10.1213/ANE.0b013e3181eac011 . PMID   20802053. S2CID   39217801.
  11. 1 2 3 Lutsep HL (June 2002). "Repinotan Bayer". Current Opinion in Investigational Drugs. 3 (6): 924–927. PMID   12137415.
  12. ↑ Kline AE, Yu J, Horváth E, Marion DW, Dixon CE (2001). "The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats". Neuroscience. 106 (3): 547–555. doi:10.1016/s0306-4522(01)00300-1. PMID   11591455. S2CID   54308982.
  13. 1 2 3 4 Teal P, Davis S, Hacke W, Kaste M, Lyden PD, Fierus M (November 2009). "A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT)". Stroke. 40 (11): 3518–3525. doi: 10.1161/strokeaha.109.551382 . PMID   19745176.
  14. ↑ Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R (July 2006). "5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease". Neurobiology of Disease. 23 (1): 77–86. doi:10.1016/j.nbd.2006.02.003. hdl:10261/59551. PMID   16545572. S2CID   19803633.
  15. ↑ Ferro JM, Dávalos A (2006). "Other neuroprotective therapies on trial in acute stroke". Cerebrovascular Diseases. 21 Suppl 2 (2): 127–130. doi:10.1159/000091712. PMID   16651823. S2CID   39193793.
  16. 1 2 3 Teal P, Silver FL, Simard D (February 2005). "The BRAINS study: safety, tolerability, and dose-finding of repinotan in acute stroke". The Canadian Journal of Neurological Sciences. Le Journal Canadien des Sciences Neurologiques. 32 (1): 61–67. doi: 10.1017/s0317167100016899 . PMID   15825548.
  17. ↑ Boettcher M, Heinig R, Wensing G, Kuhlmann J (March 2005). "Pupil reaction: a valid sensitive clinical biomarker for 5-HT compounds". Basic & Clinical Pharmacology & Toxicology. 96 (3): 246. doi:10.1111/j.1742-7843.2005.pto960317.x. PMID   15733223.
  18. ↑ Tanigawa T, Heinig R, Kuroki Y, Higuchi S (February 2006). "Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach" (PDF). Drug Metabolism and Pharmacokinetics. 21 (1): 61–69. doi:10.2133/dmpk.21.61. PMID   16547395. S2CID   10517194. Archived from the original (PDF) on 2020-02-07.
  19. ↑ De Vry J, Schohe-Loop R, Heine HG, Greuel JM, Mauler F, Schmidt B, et al. (March 1998). "Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist". The Journal of Pharmacology and Experimental Therapeutics. 284 (3): 1082–1094. PMID   9495870.
  20. ↑ Adayev T, Ray I, Sondhi R, Sobocki T, Banerjee P (April 2003). "The G protein-coupled 5-HT1A receptor causes suppression of caspase-3 through MAPK and protein kinase Calpha". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1640 (1): 85–96. doi: 10.1016/s0167-4889(03)00023-5 . PMID   12676358.
  21. ↑ Díaz-Mataix L, Artigas F, Celada P (May 2006). "Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by a 5-HT1A receptor agonist". European Neuropsychopharmacology. 16 (4): 288–296. doi:10.1016/j.euroneuro.2005.10.003. hdl:10261/34586. PMID   16290106. S2CID   38788669.
  22. ↑ Díaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F (November 2005). "Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action". The Journal of Neuroscience. 25 (47): 10831–10843. doi:10.1523/jneurosci.2999-05.2005. PMC   6725886 . PMID   16306396.
  23. 1 2 Schwarz T, Beckermann B, Buehner K, Mauler F, Schuhmacher J, Seidel D, et al. (September 2005). "Pharmacokinetics of repinotan in healthy and brain injured animals". Biopharmaceutics & Drug Disposition. 26 (6): 259–268. doi:10.1002/bdd.458. PMID   15966026. S2CID   25596274.
  24. ↑ Teal P, Davis S, Hacke W, Kaste M, Lyden PD, Fierus M (November 2009). "A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT)". Stroke. 40 (11): 3518–3525. doi: 10.1161/STROKEAHA.109.551382 . PMID   19745176.
  25. ↑ Heinig R, Sundaresan P, Shah A, Boettcher M (2005). "Effect of gender and age on the pharmacokinetics of repinotan". Clinical Drug Investigation. 25 (2): 125–134. doi:10.2165/00044011-200525020-00005. PMID   17523762. S2CID   40485277.
  26. 1 2 Heinig R, Böttcher MF (2005). "Pharmacokinetics of escalating doses of intravenous repinotan in healthy male volunteers". Clinical Drug Investigation. 25 (2): 115–123. doi:10.2165/00044011-200525020-00004. PMID   17523761. S2CID   23415230.
  27. 1 2 3 4 5 6 Seidel D, Conrad M, Schoof Y, Schohe-Loop R (November 2002). "Synthesis of [14C]-labelled repinotan hydrochloride and its major metabolite M-6". Journal of Labelled Compounds and Radiopharmaceuticals. 45 (13): 1115–1132. doi:10.1002/jlcr.629.
  28. ↑ "PubChem- Repinotan". PubChem. National Center for Biotechnology Information, U.S. National Library of Medicine. Retrieved 10 November 2014.
  29. ↑ US 5300523,Junge B, Schohe R, Seidel PR, Glaser T, Traber J, Benz U, Schuurman T, De Vry JM,issued 1994, assigned to Bayer Healthcare AG.
  30. ↑ US 5830908,Grunenberg A, Brehm O, Conrad M, Seidel D,issued 1998, assigned to Bayer AG.
  31. ↑ Gross JL (November 2003). "A concise stereospecific synthesis of repinotan (BAY× 3702)". Tetrahedron Letters. 44 (47): 8563–8565. doi:10.1016/j.tetlet.2003.09.130.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.